In this series we explore the trends and forces behind the two leading causes of death in the United States: cancer and heart disease.
Join us as we interview guest speakers, patient advocates and industry experts to dive deep into the confluence of forces at work behind these two high cost and complex specialties.
Our associate chief medical officer shares her insights with the American Journal of Managed Care's podcast.
Learn why underuse is a major problem and how we might tackle it
GDMT, or guideline-directed medical therapy, means taking the right medication at the optimal doses to treat cardiovascular problems. Yet these medications are chronically underused.
Every day, cardiologists make decisions about what is the most appropriate test, therapy, or procedure for their patients. But then COVID-19 came along. Have the rules of the game changed?
From cytotoxic chemotherapy to targeted therapy: we’ve entered a new era of cancer care. What is life like as a provider in this new era? How can oncologists keep up with the latest science?
Palliative care—supportive care—is a glaring need in cancer care, but myths, misconceptions and mixed messages create barriers for broader palliative program implementation.
The therapeutic landscape in oncology is vast and everchanging, marked by a dramatic pace of innovation and new approvals. In this complicated specialty, how can payers and providers keep up?
There is tremendous excitement around the concept of precision oncology. But how many patients will truly benefit from these treatments? And do the results for these patients justify the hype?
Ashley Ridlon shares her insights into ways CMS can build on the benefits and momentum of the OCM and improve the program to help providers succeed in this model.
Rani Khetarpal explores what the OCM model looks like at one oncology practice in Illinois and how the program can improve to help more organizations improve care delivery and generate savings.
Ed Bassin, SVP Provider Specialty Solutions, discusses the key components, benefits, challenges and financial incentives involved in the CMS Oncology Care Model (OCM).
